Amid Concerns Over Alteogen's SC Enzyme, Industry Stresses "Patent and Performance Advantage"
ALT-B4 Secures U.S. Patent Protection Until 2043
Targeting the Original SC Formulation Market
"Distinguished from PH20 Biosimilars"
There has recently been speculation that Alteogen is exposed to the risk of being chased by latecomers such as Samsung Bioepis in the subcutaneous injection (SC) formulation conversion enzyme market, drawing significant attention from investors and the industry. Some interpret the recent criticism as a sign that Alteogen’s competitiveness is weakening, whereas others counter that such concerns are exaggerated since the application areas of each company’s enzymes are fundamentally different.
According to the bio industry on July 21, SC formulation conversion enzymes are technologies that improve dosing convenience by converting intravenous (IV) biologics into subcutaneous formulations, making this segment a fierce battleground in the biopharmaceutical industry recently. For original drug makers, these enzymes present a solution to extend market exclusivity after patent expiry, while for biosimilar companies, they offer a tool for differentiation. With the substance patent for the original innovator, Halozyme’s ENHANZE, set to expire in the United States in 2027, companies including Alteogen, Samsung Bioepis, Celltrion, and Huons are entering the market one after another.
Until now, Alteogen has been evaluated as the leader in this market. This is because ALT-B4, backed by patents, established itself in the original market with a differentiation from copycat enzymes and, reportedly, has secured evidence of superior enzyme performance compared to competing substances.
According to those familiar with the US patent litigation between Merck (MSD) and Halozyme regarding alleged infringement of the ENHANZE substance patent, experimental data submitted by Halozyme in the UK patent dispute actually showed that the enzyme activity of ALT-B4 was higher than that of PH20.
A higher enzyme activity means hyaluronan can be broken down more efficiently with the same dosage or achieve the same effect with a smaller amount. This lawsuit concluded in March, as Halozyme voluntarily withdrew the relevant patent just before submitting the final evidence, resulting in a victory for MSD. With both patent rights and performance demonstrated, this is cited as a key reason why Alteogen is seen as a leader in the original SC formulation conversion market.
There is also an assessment that Alteogen maintains an advantage in patent structure. Alteogen’s ALT-B4 is a novel hyaluronidase with a US substance patent secured through 2043, which original pharmaceutical companies can use as part of their SC formulation patent strategies. Notably, MSD has secured US patent protection until 2043 for “Keytruda SC (QUREX),” an SC formulation of Keytruda (whose US substance patent expires in 2028) in combination with ALT-B4.
The hyaluronidase being developed by Samsung Bioepis and others is essentially a copy of Halozyme’s product and is not patented. Because exclusivity cannot be extended, original drug makers have little incentive to adopt these products. As a result, the copy enzyme is likely to be used mainly by biosimilar companies for their own products. This implies that the patents and application markets have diverged from the outset.
The securities industry also assessed that this issue has a limited impact on Alteogen’s competitiveness. Hana Securities maintained its ‘buy’ recommendation on Alteogen and a target share price of 5.8 million won in a report released on July 16. Sunah Kim, a researcher at Hana Securities, stated, “This hyaluronidase issue is not about the development of a new enzyme, but pertains to ENHANZE biosimilars,” and analyzed, “ALT-B4 will maintain its competitiveness by virtue of its differentiated antibody delivery capability and storage stability.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Taeyeon Jeon, CEO of Alteogen, commented in a phone interview with a reporter, “We will not be swayed by external noise and controversy, and will continue striving to enhance shareholder value.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.